Literature DB >> 19151639

The price of success: cost-effectiveness of molecularly targeted agents.

S Sleijfer1, J Verweij.   

Abstract

The advent of molecularly targeted agents has brought major breakthroughs in oncology. However, because these drugs are expensive and financial resources are limited, attention to their cost-effectiveness is rapidly increasing. It seems that establishment of cost-effectiveness is complex but is determined for the most part by the cost of drug acquisition and the drug's efficacy. This article examines the cost-effectiveness of molecularly targeted drugs.

Mesh：

Substances：

Year:  2009        PMID： 19151639     DOI： 10.1038/clpt.2008.245

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Authors:  Jaap Verweij; Maja de Jonge; Ferry Eskens; Stefan Sleijfer
Journal:  Mol Oncol       Date:  2012-02-16       Impact factor: 6.603

2.  Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.

Authors:  George Poste; David P Carbone; David R Parkinson; Jaap Verweij; Stephen M Hewitt; J Milburn Jessup
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

Review 3.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

Review 4.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

5.  Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.

Authors:  Piotr Rutkowski; Alessandro Gronchi
Journal:  Oncologist       Date:  2013-05-24

6.  Advances in cancer therapeutics.

Authors:  A Sparreboom; J Verweij
Journal:  Clin Pharmacol Ther       Date:  2009-02       Impact factor: 6.875

7.  Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.

Authors:  S De Groot; H M Blommestein; W K Redekop; S Sleijfer; L A L M Kiemeney; E Oosterwijk; C A Uyl-de Groot
Journal:  PLoS One       Date:  2017-05-22       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.